Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Second interchangeable biosimilar product approved by agency
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
Subscribe To Our Newsletter & Stay Updated
